AZ505: A Potent and Selective SMYD2 Inhibitor for Epigenetic Regulation Research

Executive Summary: AZ505 is a small molecule inhibitor that targets SMYD2, a protein lysine methyltransferase involved in histone and non-histone methylation, with high potency (IC50 = 0.12 μM) and selectivity (minimal activity on SMYD3, DOT1L, EZH2) [APExBIO]. AZ505 acts as a substrate-competitive inhibitor, binding the peptide substrate groove without disrupting the SAM co-factor. Peer-reviewed studies demonstrate that AZ505 inhibits SMYD2-mediated pathways in cancer and renal fibrosis models (Chen et al., 2023, DOI). AZ505 is soluble in DMSO, stable at -20°C, and recommended for use in epigenetic regulation, cancer biology, and translational fibrosis research. It is provided by APExBIO for research use only and is not suitable for diagnostic or therapeutic applications.

Biological Rationale

SMYD2 (SET and MYND domain-containing 2) is a protein lysine methyltransferase. It catalyzes methylation of histone proteins H2B, H3, and H4, as well as non-histone substrates such as p53 and Rb proteins (Chen et al., 2023). Methylation of histone H3 at lysine 36 (H3K36) by SMYD2 modulates chromatin structure and gene expression. SMYD2 is overexpressed in several cancers, including gastric cancer and esophageal squamous cell carcinoma (ESCC) (APExBIO). Elevated SMYD2 activity is associated with tumorigenesis, epithelial-mesenchymal transition (EMT), fibrosis, and inflammatory signaling. Thus, pharmacological inhibition of SMYD2 is a strategic approach for dissecting epigenetic regulation in disease models.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule that specifically inhibits SMYD2 by binding to the peptide substrate binding groove. This mechanism is substrate-competitive, preventing substrate methylation while not competing with the cofactor S-adenosylmethionine (SAM) (APExBIO). The binding of AZ505 blocks access of histone and non-histone substrates to the active site of SMYD2. The IC50 of AZ505 for SMYD2 is 0.12 μM, and the Ki is 0.3 μM, demonstrating high potency under standard biochemical assay conditions (pH 7.5, 25°C, recombinant human SMYD2) (Chen et al., 2023). AZ505 exhibits minimal inhibition of related methyltransferases (SMYD3, DOT1L, EZH2; IC50 > 83.3 μM), indicating strong selectivity.

Evidence & Benchmarks

• AZ505 inhibits SMYD2 activity in vitro with an IC50 of 0.12 μM and a Ki of 0.3 μM under standard enzymatic conditions (APExBIO).
• AZ505 displays high selectivity, with IC50 values >83.3 μM for SMYD3, DOT1L, and EZH2, minimizing off-target effects (APExBIO).
• In a cisplatin-induced chronic kidney disease (CKD) mouse model, AZ505 administration significantly reduced SMYD2 expression, improved renal function, and suppressed renal fibrosis and inflammatory cytokine production (Chen et al., 2023).
• AZ505 treatment in vitro inhibited epithelial-mesenchymal transition (EMT), fibrosis-related protein expression, and inflammatory cytokines in tubular epithelial cells exposed to cisplatin (Chen et al., 2023).
• AZ505 has been widely used for epigenetic regulation and cancer biology research, particularly in models where SMYD2 is overexpressed, such as gastric cancer and ESCC (APExBIO).

This article extends the protocol and application focus presented in AZ505, a Potent and Selective SMYD2 Inhibitor (SKU B1255)... by providing updated, peer-reviewed evidence for AZ505's impact in renal fibrosis and inflammation models, not just cancer biology.

For a mechanistic deep dive into SMYD2’s role in histone methylation and translational disease modeling, see Strategic Horizons in Epigenetic Regulation: Leveraging AZ505. This article updates those insights with recent in vivo data from CKD models.

Applications, Limits & Misconceptions

AZ505 is primarily utilized in research settings investigating the role of SMYD2 in epigenetic regulation, cancer biology, and fibrotic diseases. Its high selectivity allows researchers to dissect SMYD2-specific pathways without confounding off-target methyltransferase inhibition. AZ505 is particularly valuable in models of gastric cancer, ESCC, and renal fibrosis, where SMYD2 is implicated in disease progression. The compound is not approved for diagnostic or therapeutic use in humans or animals and is intended strictly for in vitro and in vivo research applications.

Common Pitfalls or Misconceptions

• AZ505 is not a pan-methyltransferase inhibitor; it shows minimal activity against SMYD3, DOT1L, or EZH2 (IC50 > 83.3 μM).
• The compound does not compete with the cofactor S-adenosylmethionine (SAM); it is substrate-competitive only.
• AZ505 is not suitable for clinical or diagnostic applications; it is for research use only.
• Solubility issues may arise in aqueous buffers; dissolve in DMSO first and warm (37°C) or use ultrasound if needed.
• Stability is best maintained at -20°C; repeated freeze-thaw cycles can reduce potency.

Workflow Integration & Parameters

AZ505 (SKU B1255) is supplied as a powder and should be dissolved in DMSO for stock solutions. Typical working concentrations range from 0.1 μM to 10 μM, depending on assay requirements. For optimal solubility, warm the solution to 37°C and use ultrasonic agitation if necessary. Store aliquots at -20°C to preserve stability. AZ505 is compatible with cell-based and biochemical assays assessing histone methylation, chromatin immunoprecipitation (ChIP), cell viability, and proliferation. Experimental controls should include vehicle-only (DMSO) samples. For detailed protocol guidance, see AZ505, a Potent and Selective SMYD2 Inhibitor: Data-Driven Lab Guidance, which this article updates by incorporating new CKD model findings.

Conclusion & Outlook

AZ505, a potent and selective SMYD2 inhibitor from APExBIO, enables targeted investigation of SMYD2-mediated epigenetic mechanisms in cancer, fibrosis, and inflammation. Its robust selectivity, validated efficacy in disease models, and compatibility with diverse assay systems make it a valuable tool for translational and basic research. Future directions include expanding its use in emerging models of epigenetic dysregulation and leveraging its well-characterized mechanism for drug development studies. For product details, protocols, and ordering, visit the AZ505 product page.